Verona Pharma PLC
NASDAQ:VRNA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.48
45.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Verona Pharma PLC
Verona Pharma PLC
Net Issuance of Common Stock
Verona Pharma PLC
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Net Issuance of Common Stock
$4.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Net Issuance of Common Stock
£20m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
AstraZeneca PLC
LSE:AZN
|
Net Issuance of Common Stock
$36m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-23%
|
|
|
Indivior PLC
LSE:INDV
|
Net Issuance of Common Stock
-$89m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Net Issuance of Common Stock
£181.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
71%
|
|
Verona Pharma PLC
Glance View
Verona Pharma PLC, an ambitious player in the biopharmaceutical arena, is woven into the intricate tapestry of the healthcare industry, focusing its energies on respiratory ailments. Born within the thriving biopharma sector in London, this company has targeted chronic obstructive pulmonary disease (COPD) with its novel therapies, driven by the urgent need to alleviate this global burden. The company's flagship product, ensifentrine, serves as a dual inhibitor of the enzymes phosphodiesterase 3 and 4, aiming to enhance lung function and ease the constriction challenges faced by patients. Through strategic clinical trials and robust scientific inquiry, Verona Pharma seeks not only to innovate in treatment but also to deliver tangible hope for those grappling with chronic respiratory conditions. Verona Pharma's business model is anchored in advancing its drug development pipeline, propelled by a blend of scientific rigor and strategic partnerships. It capitalizes on patent protection and licensing agreements to secure its financial footing, investing heavily in research to drive value creation. The company earns its revenue predominantly from collaborative agreements with larger pharmaceutical entities, milestone payments, and potential royalties upon successful commercialization of its therapies. Through aligning with other industry giants, Verona Pharma not only financially fortifies its pursuits but also accelerates the dissemination of its therapeutic innovations, ensuring that their beneficial impacts reach as many patients as possible. This harmonized approach with partners places Verona Pharma on a trajectory not just of financial growth but also of achieving its underlying mission – transforming the landscape of respiratory disease management.
See Also
What is Verona Pharma PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
4.5m
USD
Based on the financial report for Sep 30, 2024, Verona Pharma PLC's Net Issuance of Common Stock amounts to 4.5m USD.
What is Verona Pharma PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
48%
Over the last year, the Net Issuance of Common Stock growth was 48%.
You don't have any saved screeners yet
